The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationMutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071
Self-citationTumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Goodman, A. M., Kato, S., Bazhenova, L., Patel, S. P., Frampton, G. M., Miller, V., Stephens, P. J., Daniels, G. A., & Kurzrock, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0386 · Cited by 2,264
Self-citation
Cited by
McGrail, D. J., Pilié, P. G., Rashid, N. U., Voorwerk, L., Slagter, M., Kok, M., Jonasch, E., Khasraw, M., Heimberger, A. B., Lim, B., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.02.006 · Cited by 1,032
Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology
Abu-Rustum, N., Yashar, C., Arend, R., Barber, E., Bradley, K., Brooks, R., Campos, S. M., Chino, J., Chon, H. S., Chu, C., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0006 · Cited by 568
Palmeri, M., Mehnert, J., Silk, A. W., Jabbour, S. K., Ganesan, S., Popli, P., Riedlinger, G., Stephenson, R., de Meritens, A. B., Leiser, A., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2021.100336 · Cited by 350
Self-citationArtificial Intelligence for Predictive Biomarker Discovery in Immuno-Oncology: A Systematic Review
Prelaj, A., Miskovic, V., Zanitti, M., Trovo, F., Genova, C., Viscardi, G., Rebuzzi, S. E., Mazzeo, L., Provenzano, L., Kosta, S., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.125 · Cited by 340
Targeting the DNA damage response in immuno-oncology: developments and opportunities
Chabanon, R. M., Rouanne, M., Lord, C. J., Soria, J.-C., Pasero, P., & Postel-Vinay, S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00386-6 · Cited by 293
Metadata
- Authors
- Subbiah, V., Solit, D. B., Chan, T. A., & Kurzrock, R.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 31
- Issue
- 9
- Pages
- 1115-1118
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W3047253098
- Cited by
- 252
- References
- 5
- FWCI
- 12.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians. https://app.cochat.ai/papers/10.1016/j.annonc.2020.07.002
- The paper
- Subbiah, V., Solit, D. B., Chan, T. A., & Kurzrock, R. (2020). The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians. Annals of Oncology. https://doi.org/10.1016/j.annonc.2020.07.002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.